Get the Stockscreener App
4.15
0.24%
0.01
Pre-market:
4.00
-0.15
-3.61%
Tuhura Biosciences Inc stock is traded at $4.15, with a volume of 117.44K.
It is up +0.24% in the last 24 hours and up +71.49% over the past month.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
See More
Previous Close:
$4.14
Open:
$4.17
24h Volume:
117.44K
Relative Volume:
0.54
Market Cap:
$183.46M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+7.24%
1M Performance:
+71.49%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$3.91
$4.25
1-Week Range:
$3.67
$4.25
52-Week Range:
$1.80
$7.20
Tuhura Biosciences Inc Stock (HURA) Company Profile
Name
Tuhura Biosciences Inc
Sector
Industry
Phone
813-875-6600
Address
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
4.15 | 183.46M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-25 | Initiated | H.C. Wainwright | Buy |
| Dec-19-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-05-24 | Initiated | Maxim Group | Buy |
Tuhura Biosciences Inc Stock (HURA) Latest News
Is TuHURA Biosciences, Inc. (HURA) the Best Rising Penny Stock to Buy According to Analysts? - Insider Monkey
Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study - Quantisnow
Equities Analysts Offer Predictions for HURA Q3 Earnings - Defense World
HURA: 2024 Financial Results - Zacks Small Cap Research
TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting - PR Newswire
TuHURA Biosciences hires new EVP for drug development By Investing.com - Investing.com South Africa
TuHURA Biosciences hires new EVP for drug development - Investing.com India
Tuhura Biosciences Appoints Dr. Bertrand Le Bourdonnec As Executive Vice President - MarketScreener
TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management - PR Newswire
Q2 EPS Estimate for TuHURA Biosciences Increased by Analyst - Defense World
Q3 Earnings Estimate for HURA Issued By HC Wainwright - Defense World
HC Wainwright Has Lowered Expectations for TuHURA Biosciences (NASDAQ:HURA) Stock Price - Defense World
H.C. Wainwright cuts TuHURA Biosciences target to $12; Keeps Buy By Investing.com - Investing.com South Africa
H.C. Wainwright cuts TuHURA Biosciences target to $12; Keeps Buy - Investing.com
Is TuHURA Biosciences (NASDAQ:HURA) In A Good Position To Deliver On Growth Plans? - Yahoo
Charles Schwab Investment Management Inc. Purchases New Position in TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 - TradingView
TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update - PR Newswire
TuHURA Biosciences (NASDAQ:HURA) Stock Price Up 1.7% – Still a Buy? - Defense World
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
TuHURA Biosciences Announces Acquisition of Kineta, Inc. - MSN
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
TuHURA Biosciences Expands Board with New Appointment - TipRanks
TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors - Joplin Globe
TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference - Eagle-Tribune
What is HC Wainwright’s Estimate for HURA Q2 Earnings? - Defense World
KINETA, INC./DE SEC 10-K Report - TradingView
TuHURA Biosciences (NASDAQ:HURA) Now Covered by Analysts at HC Wainwright - Defense World
HC Wainwright Initiates TuHURA Biosciences at Buy With $13 Price Target -March 03, 2025 at 07:29 am EST - Marketscreener.com
TuHURA Biosciences (HURA) to Release Earnings on Wednesday - Defense World
TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - Milton Daily Standard
Press Release Distribution & PR Platform - ACCESS Newswire
Apollon Wealth Management LLC Invests $253,000 in TuHURA Biosciences (NASDAQ:HURA) - MarketBeat
TuHURA Biosciences: A Hold On Only The Faintest Glimmers Of Efficacy (NASDAQ:HURA) - Seeking Alpha
TuHURA Biosciences secures $3M through warrant exercises By Investing.com - Investing.com Australia
TuHURA Biosciences secures $3M through warrant exercises - Investing.com India
Tuhura Biosciences Inc Stock (HURA) Financials Data
There is no financial data for Tuhura Biosciences Inc (HURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):